# A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

> **NCT07650084** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 75 (estimated)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** BLU-5937
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07650084
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-21
- **Primary completion:** 2027-08-27
- **Final completion:** 2028-06-02
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650084, "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*